{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-237196","form_type":"8-K","ticker":"CLYM","cik":"0001768446","company_name":"Climb Bio, Inc.","filed_at":"2024-10-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.536199+00:00","generated_at":"2026-05-30T14:40:33.836740+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"medium","headline":"Climb Bio outlines budoprutug development strategy; Phase 1b pMN data shows 60% remission","bullets":["Approximately $218M cash at Sept 30, 2024; expected to fund operations through 2027.","Phase 1b pMN: 3/5 patients achieved complete remission; rapid B-cell depletion and anti-PLA2R reductions.","Plans to initiate Phase 1b SLE trial and Phase 2 ITP trial in first half 2025, subject to regulatory clearance.","Subcutaneous formulation advancing; non-clinical data expected first half 2025.","Full pMN Phase 1b data to be presented at ASN Kidney Week on Oct 24, 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-237196","json":"https://secwatch.observer/filing/0001193125-24-237196.json","markdown":"https://secwatch.observer/filing/0001193125-24-237196.md","text":"https://secwatch.observer/filing/0001193125-24-237196.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1768446/000119312524237196/0001193125-24-237196-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1768446/000119312524237196/d889682d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T14:40:33.836740+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}